1993
Trends in the Incidence of Outcomes Defining Acquired Immunodeficiency Syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985–1991
Muñoz A, Schrager L, Bacellar H, Speizer I, Vermund S, Detels R, Saah A, Kingsley L, Seminara D, Phair J. Trends in the Incidence of Outcomes Defining Acquired Immunodeficiency Syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985–1991. American Journal Of Epidemiology 1993, 137: 423-438. PMID: 8096356, DOI: 10.1093/oxfordjournals.aje.a116691.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsCD4-Positive T-LymphocytesCohort StudiesCytomegalovirus InfectionsHerpes SimplexHIV SeropositivityHIV-1HumansIncidenceLeukocyte CountLymphomaMaleNervous System DiseasesPneumonia, PneumocystisProspective StudiesRegression AnalysisRisk FactorsSarcoma, KaposiUnited StatesConceptsAcquired Immunodeficiency SyndromeP. carinii pneumoniaCarinii pneumoniaProgressive immunosuppressionKaposi's sarcomaImmunodeficiency syndromeOpportunistic infectionsHerpes simplex virus infectionHuman immunodeficiency virus type 1Multicenter AIDS Cohort StudyImmunodeficiency virus type 1Use of chemoprophylaxisUse of prophylaxisIncidence of outcomesPneumocystis carinii pneumoniaSimplex virus infectionAIDS Cohort StudyVirus type 1Antiretroviral therapyCohort studyClinical outcomesInitial diagnosisSecondary diagnosisLower incidenceNeurologic diseaseCD4+ Counts in Seronegative Homosexual Men
Vermund S, Hoover D, Chen K. CD4+ Counts in Seronegative Homosexual Men. New England Journal Of Medicine 1993, 328: 442. PMID: 8093639, DOI: 10.1056/nejm199302113280615.Peer-Reviewed Original Research
1992
The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection
Graham N, Zeger S, Park L, Vermund S, Detels R, Rinaldo C, Phair J. The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 326: 1037-1042. PMID: 1347907, DOI: 10.1056/nejm199204163261601.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSPneumocystis carinii pneumoniaPCP prophylaxisProlong survivalEarly treatmentRelative riskVirus infectionCell countUse of zidovudineUse of prophylaxisDiagnosis of AIDSHIV Type 1HIV-1 infectionBasis of CD4High-risk menInitial disease stateProbability of deathZidovudine usersZidovudine therapyImmunodeficiency syndromeCarinii pneumoniaClinical symptomsProphylaxisCD4+ Lymphocyte Cell Enumeration for Prediction of Clinical Course of Human Immunodeficiency Virus Disease: A Review
Stein D, Korvick J, Vermund S. CD4+ Lymphocyte Cell Enumeration for Prediction of Clinical Course of Human Immunodeficiency Virus Disease: A Review. The Journal Of Infectious Diseases 1992, 165: 352-363. PMID: 1346152, DOI: 10.1093/infdis/165.2.352.Peer-Reviewed Original ResearchConceptsCell countHuman immunodeficiency virus (HIV) diseaseHuman immunodeficiency virus (HIV) infectionIntercurrent viral infectionPractical clinical perspectiveProgressive infectious processImmunodeficiency virus infectionImportant therapeutic decisionsAIDS CommentaryInfluence of drugsT helperClinical courseHIV infectionSurrogate markerTherapeutic decisionsVirus infectionInfectious processViral infectionCD4Clinical perspectiveEnd stageInfectionNational InstituteVirus diseaseCount
1991
Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS
STUDY T, Graham N, Zeger S, Park L, Saah A, Phair J, Detels R, Vermund S, Ho M. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Lancet 1991, 338: 265-269. PMID: 1677108, DOI: 10.1016/0140-6736(91)90414-k.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAerosolsCD4-Positive T-LymphocytesEvaluation Studies as TopicFollow-Up StudiesHIV SeropositivityHIV-1HumansLeukocyte CountMalePentamidinePneumonia, PneumocystisProspective StudiesRegression AnalysisRisk FactorsTime FactorsTrimethoprim, Sulfamethoxazole Drug CombinationZidovudineConceptsPneumocystis carinii pneumoniaEffect of zidovudineHIV-1 infectionPCP prophylaxisProbability of progressionLymphocytes/First episodePneumocystis carinii pneumonia prophylaxisHIV-1-infected individualsHIV-1-seropositive menMonth intervalsPrimary PCP prophylaxisEfficacy of zidovudinePresence of HIVRate of progressionMultivariate log-linear modelPneumonia prophylaxisMore CD4Primary prophylaxisZidovudine therapyLymphocyte countCarinii pneumoniaClinical trialsObservational studyProphylaxis